J
John K. Camoriano
Researcher at Mayo Clinic
Publications - 71
Citations - 3562
John K. Camoriano is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Myelofibrosis & Ruxolitinib. The author has an hindex of 27, co-authored 71 publications receiving 3288 citations. Previous affiliations of John K. Camoriano include University of Missouri & University of Rochester.
Papers
More filters
Journal ArticleDOI
The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.
Ruben A. Mesa,Joyce Niblack,Martha Wadleigh,Srdan Verstovsek,John K. Camoriano,Sunni A. Barnes,Angelina D. Tan,Pamela J. Atherton,Jeff A. Sloan,Ayalew Tefferi +9 more
TL;DR: Few objective data exist on the burden of fatigue and other constitutional symptoms in patients with myeloproliferative disorders (MPD) and how these symptoms change with age and disease progression.
Journal ArticleDOI
Randomized Comparison of Megestrol Acetate Versus Dexamethasone Versus Fluoxymesterone for the Treatment of Cancer Anorexia/Cachexia
Charles L. Loprinzi,John W. Kugler,Jeff A. Sloan,James A. Mailliard,James E. Krook,Mary B. Wilwerding,Kendrith M. Rowland,John K. Camoriano,Paul J. Novotny,Bradley J. Christensen +9 more
TL;DR: Whereas fluoxymesterone clearly seems to be an inferior choice for treating cancer anorexia/cachexia, megestrol acetate and dexamethasone have similar appetite stimulating efficacy but differing toxicity profiles.
Journal ArticleDOI
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
Ayalew Tefferi,Giovanni Barosi,Ruben A. Mesa,Francisco Cervantes,H. Joachim Deeg,John T. Reilly,Srdan Verstovsek,Brigitte Dupriez,Richard T. Silver,Olatoyosi Odenike,Jorge E. Cortes,Martha Wadleigh,Lawrence A. Solberg,John K. Camoriano,Heinz Gisslinger,Pierre Noel,Juergen Thiele,James W. Vardiman,Ronald Hoffman,Nicholas C.P. Cross,D. Gary Gilliland,Hagop M. Kantarjian +21 more
TL;DR: An international panel of experts recently convened and delineated 3 response categories: complete remission (CR), partial remission (PR), and clinical improvement (CI).
Journal ArticleDOI
Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer.
John K. Camoriano,Charles L. Loprinzi,James N. Ingle,Terry M. Therneau,James E. Krook,Michael H. Veeder +5 more
TL;DR: It is concluded that, relative to observation, adjuvant chemotherapy is associated with greater weight gain in node-positive, postmenopausal breast cancer patients, and in premenopausal women, excessive weight gain may be associated with an increase in relapse and cancer-related deaths in the selected patients who show no evidence of recurrence during 60 weeks of adjUvant chemotherapy.
Journal ArticleDOI
The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis
Ruben A. Mesa,Susan M. Schwager,Deepti Radia,Andrea L. Cheville,Kebede Hussein,Joyce Niblack,Animesh Pardanani,David P. Steensma,Mark R. Litzow,Candido E. Rivera,John K. Camoriano,Srdan Verstovsek,Jeff A. Sloan,Claire N. Harrison,Hagop M. Kantarjian,Ayalew Tefferi +15 more
TL;DR: A 20-item instrument (MFSAF): Myelofibrosis Symptom Assessment Form which measures the symptoms reported by >10% of MF patients and includes a measure of QoL should be considered for evaluation of MF symptoms in therapeutic clinical trials.